Fluorescence‐Quenching Lateral Flow Immunoassay for “Turn‐On” and Sensitive Detection of Anti‐SARS‐Cov‐2 Neutralizing Antibodies in Human Serum
Advanced Science · 2024-01 · 11 (4)
DOI: 10.1002/advs.202305774 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 30.11.2023. Verfasst von Lun Bian und 7 weiteren Autor:innen. Beteiligte Einrichtung: Biomaterials Research Center, School of Biomedical Engineering, Southern Medical University, Guangzhou, 510515, China. Hauptthemen laut MEDLINE: COVID-19, Metal Nanoparticles. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Guangzhou Municipal Science and Technology Bureau.
Abstract (Originalsprache)
The titer of anti‐severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) neutralizing antibodies (NAbs) in the human body is an essential reference for evaluating the acquired protective immunity and resistance to SARS‐CoV‐2 infection. In this study, a fluorescence‐quenching lateral flow immunoassay (FQ‐LFIA) is established for quantitative detection of anti‐SARS‐CoV‐2 NAbs in the sera of individuals who are vaccinated or infected within 10 min. The ultrabright aggregation‐induced emission properties encapsulated in nanoparticles, AIE 490 NP, are applied in the established FQ‐LFIA with gold nanoparticles to achieve a fluorescence “turn‐on” competitive immunoassay. Under optimized conditions, the FQ‐LFIA quantitatively detected 103 positive and 50 negative human serum samples with a limit of detection (LoD) of 1.29 IU mL −1 . A strong correlation is present with the conventional pseudovirus‐based virus neutralization test ( R 2 = 0.9796, P < 0.0001). In contrast, the traditional LFIA with a “turn‐off” mode can only achieve a LoD of 11.06 IU mL −1 . The FQ‐LFIA showed excellent sensitivity to anti‐SARS‐CoV‐2 NAbs. The intra‐ and inter‐assay precisions of the established method are below 15%. The established FQ‐LFIA has promising potential as a rapid and quantitative method for detecting anti‐SARS‐CoV‐2 NAbs. FQ‐LFIA can also be used to detect various biomarkers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biomaterials Research Center, School of Biomedical Engineering, Southern Medical University, Guangzhou, 510515, China.
- Department of Laboratory Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
- Division of Laboratory Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282, China.
Förderung
- Guangzhou Municipal Science and Technology Bureau
Zitieren
APA
Bian, L., Fu, Q., Gan, Z., Wu, Z., Song, Y., Xiong, Y., Hu, F., & Zheng, L. (2024). Fluorescence‐Quenching Lateral Flow Immunoassay for “Turn‐On” and Sensitive Detection of Anti‐SARS‐Cov‐2 Neutralizing Antibodies in Human Serum. Advanced Science, 11(4). https://doi.org/10.1002/advs.202305774
Vancouver
Bian L, Fu Q, Gan Z, Wu Z, Song Y, Xiong Y, et al. Fluorescence‐Quenching Lateral Flow Immunoassay for “Turn‐On” and Sensitive Detection of Anti‐SARS‐Cov‐2 Neutralizing Antibodies in Human Serum. Advanced Science. 2024;11(4). doi:10.1002/advs.202305774
BibTeX
@article{Bian2024,
author = {Bian, Lun and Fu, Qiangqiang and Gan, Zhuoheng and Wu, Ze and Song, Yuchen and Xiong, Yufeng and Hu, Fang and Zheng, Lei},
title = {Fluorescence‐Quenching Lateral Flow Immunoassay for “Turn‐On” and Sensitive Detection of Anti‐SARS‐Cov‐2 Neutralizing Antibodies in Human Serum},
journal = {Advanced Science},
year = {2024},
volume = {11},
number = {4},
doi = {10.1002/advs.202305774}
}
EUVIMED